All Names: Selpercatinib,Retevmo,LOXO-292
Indications:1. Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer; 2. RET-Mutant Medullary Thyroid Cancer; 3. RET Fusion-Positive Thyroid Cancer
Manufacturer:Eli Lilly,USA
Customs Clearance Procedure:If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE(适应症)
Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
RETEVMO™ is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
RET-Mutant Medullary Thyroid Cancer
RETEVMO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
RET Fusion-Positive Thyroid Cancer
RETEVMO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
DOSAGE(服用剂量)
The recommended dosage of RETEVMO based on body weight is:
Less than 50 kg: 120 mg
50 kg or greater: 160 mg
Take RETEVMO orally twice daily (approximately every 12 hours) until disease progression or unacceptable toxicity.
Swallow the capsules whole. Do not crush or chew the capsules.
Do not take a missed dose unless it is more than 6 hours until next scheduled dose.
If vomiting occurs after RETEVMO administration, do not take an additional dose and continue to the next scheduled time for the next dose.
ADVERSE REACTIONS(不良反应)
Hepatotoxicity
Hypertension
QT Interval Prolongation
Hemorrhagic Events
Hypersensitivity
Tumor Lysis Syndrome
Risk of Impaired Wound Healing
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/7fa848ba-a59c-4144-9f52-64d090f4d828/spl-doc?hl=Selpercatinib
Retevmoinformation
No information yet!!!